ANGPT1 and neoplasm: To examine the potential of Ang1 and Ang2 inhibitors to alter tumor phenotype, OV17-1 and MDA-MB-231 cell cultures were exposed for 3 days to the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or Fc control (human IgG1-Fc at 26 μg/mL) and then analyzed for expression of human leukocyte antigen (HLA)-A2, carcinoembryonic antigen (CEA), mucin (MUC)-1, ICAM-1 (CD54), calreticulin, Fas (CD95), Trail-R1, and Trail-R2.